BriaCell Therapeutics Corp Dossier - Source-backed chat

BriaCell Therapeutics Corp

BCTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.35

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.11Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $35.8M

Enterprise Value $28.9M

Shares Outstanding 8.7M diluted

Next Earnings Date6 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel targeted immunotherapies for cancer, with a primary focus on advanced metastatic breast cancer (MBC). The investment thesis centers on the company's lead candidate, Bria-IMT™, which is currently being evaluated in a pivotal Phase 3 combination study (BRIA-ABC) under FDA Fast Track Designation. Recent clinical data presented at ASCO 2026 and AACR 2026 demonstrate robust overall survival signals, sustained quality of life, and a favorable safety profile in heavily pretreated patients, including those resistant to antibody-drug conjugates (ADCs) and checkpoint inhibitors. While the clinical pipeline is highly promising and has been recognized by Nature Medicine as one of the key trials shaping medicine in 2026, BriaCell faces significant financial risks. The company has flagged a going concern risk due to an accumulated deficit of $134.3 million and high cash burn from accelerated clinical trials, leading to substantial shareholder dilution from recent equity offerings. A 'Buy' recommendation is supported by the high-impact near-term catalyst of the Phase 3 interim overall survival readout, which could pave the way for full FDA approval, provided the company successfully manages its capital requirements.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.6020%

The Phase 3 BRIA-ABC trial fails to show a statistically significant overall survival benefit compared to the physician's choice arm at the interim analysis, or exhibits unexpected safety concerns that halt the trial. Consequently, the FDA does not grant approval. Unable to secure further non-dilutive grants or clinical partnerships, and facing delisting pressures from Nasdaq due to a depressed share price and market cap, the company is forced to halt its pipeline development or undergo a highly dilutive restructuring.

Base CaseCentral scenario

$5.3950%

The Phase 3 BRIA-ABC trial continues to enroll patients and shows positive interim safety and efficacy trends, maintaining its Fast Track momentum. The company reports topline interim overall survival data that is supportive of regulatory filing, though it may require additional follow-up. To fund operations through the regulatory process, BriaCell executes controlled, dilutive capital raises or utilizes its active warrant classes (BCTXL, BCTXZ). The stock trades in line with average analyst targets as clinical milestones are met.

Bull CaseUpside scenario

$7.2230%

The pivotal Phase 3 BRIA-ABC trial meets its primary endpoint of overall survival at the interim analysis (144 events), demonstrating a statistically significant and clinically meaningful improvement over the physician's choice comparator. Bria-IMT™ receives accelerated or full FDA approval, establishing a new standard of care for late-stage metastatic breast cancer. The company successfully leverages this success to secure a lucrative global co-development and commercialization partnership with a major pharmaceutical firm, resolving its going concern risk and funding the expansion of its personalized off-the-shelf platform (Bria-OTS™) into prostate, lung, and ovarian cancers.

Scenarios reflect our research view at the research date.

Key Investment Merits

Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial (BRIA-ABC) for metastatic breast cancer, a high-unmet-need indication with FDA Fast Track Designation.
Clinical data presented at ASCO 2026 showed strong survival signals (median overall survival up to 16.6 months in Phase 2) and preservation of patient quality of life without severe toxicities.
Independent validation by Nature Medicine, which featured the BRIA-ABC trial as one of the 'Eleven clinical trials that will shape medicine in 2026'.
Platform scalability with Bria-OTS™ and Bria-OTS+™ expanding the pipeline into other solid tumors like prostate and lung cancer, supported by non-dilutive grants such as the NCI SBIR award.

Key Investment Risks

Going concern risk highlighted by management, driven by an accumulated deficit of $134.3 million and operating cash outflows of $22.7 million for the nine months ended April 30, 2026.
Severe shareholder dilution, with common shares outstanding increasing from 1.88 million to 8.70 million within less than a year due to aggressive equity financing.
Regulatory and clinical trial execution risks inherent to late-stage oncology drug development, where failure to meet the primary overall survival endpoint would invalidate the investment case.
Nasdaq listing compliance risks related to maintaining minimum bid price and market value of listed securities requirements.

Thesis Invalidation Triggers

Failure of the Phase 3 BRIA-ABC trial to meet its primary overall survival endpoint at the interim analysis.
Inability to secure additional capital or strategic partnerships before existing cash reserves ($22.8 million as of April 30, 2026) are exhausted, leading to insolvency or a halt in clinical operations.
Safety signals or severe adverse events in the Phase 3 trial leading to a clinical hold by the FDA.
Delisting of BriaCell's common shares from the Nasdaq Capital Market due to non-compliance with listing standards.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.